Table 14.
Efficacy of 12.5 mg ombitasvir + 75 mg paritaprevir + 50 mg ritonavir fixed-dose two pills QD plus 250 mg dasabuvir BID plus ribavirin for 12w.
| Cirrhosis | Prior treatment | SVR12 rate in GT-1 | Study and trial phase | Ref. |
|---|---|---|---|---|
| No cirrhosis |
Naïve | 95% (38/40) a | AVIATOR, phase 2b | Kowdley et al., 2014b |
| Null response | 95.5% (21/22) a | |||
| Naïve | 97.2% (35/36) | Phase 2 | Lalezari et al., 2015 | |
| Experienced | 100% (2/2) | |||
| Null response | 1b:93.5% (29/31) | PEARL-II, phase 3 | Andreone et al., 2014 | |
| Partial response | 1b:96% (24/25) | |||
| Relapse | 1b:100% (32/32) | |||
| Naïve | 1a: 97% (97/100), 1b:99.5% (209/210) | PEARL-IV, PEARL-III, phase 3 | Ferenci et al., 2014 | |
| Naïve | 1a: 97.1% (67/69), 1b: 98.8% (83/84) | MALACHITE-I | Dore et al., 2016a | |
| Null response | 100% (49/49) | MALACHITE-II, phase 3 | ||
| Partial response | 100% (25/25) | |||
| Relapse | 96.3% (26/27) | |||
| Naïve | 1a:95.3% (307/322), 1b:98% (148/151) | SAPPHIRE-I, phase 3 | Feld et al., 2014 | |
| Null response | 95.3% (82/86) | SAPPHIRE-II, phase 3 | Zeuzem et al., 2014c | |
| Partial response | 100% (65/65) | |||
| Relapse to PegIFNα+RBV | 95.2% (139/146) | |||
| Naïve, stage 4/5 chronic kidney disease | 1a: 84.6% (11/13) | RUBY-I, phase 3 | Pockros et al., 2016 | |
| Naïve | 1a:95% (689/725), 1b:98.6% (140/142) | Real-world study |
Ioannou et al., 2016 |
|
| Experienced | 1a:94.6% (212/224), 1b:97.9% (47/48) | |||
| Cirrhosis | Naïve | 1a: 92.2% (59/64), 1b:100% (22/22) | TURQUOISE-II, phase 3 | Poordad et al., 2014 |
| Null response to PegIFNα/RBV | 1a:80% (40/50), 1b:100% (25/25) | |||
| Partial response to PegIFNα/RBV | 1a: 100% (11/11), 1b:85.7% (6/7) | |||
| Relapse to PegIFNα/RBV | 1a: 93.3% (14/15), 1b:100% (14/14) | |||
| Naïve | 1a:95.5% (190/199), 1b:100% (133/133) | Real-world study | Ioannou et al., 2016 | |
| Experienced | 1a:96.6% (56/58), 1b:100% (60/60) | |||
a
SVR24 rates were evaluated in the clinical study.